Related Experiment Videos

Drug resistance molecules: lessons from oncology

George L Scheffer1, Rik J Scheper

  • 1Department of Pathology, Free University Medical Center, Amsterdam, The Netherlands.

Novartis Foundation Symposium
|May 7, 2002
PubMed

Insights

Researchers developed monoclonal antibodies to study multidrug resistance (MDR) in cancer. These antibodies target proteins like P-glycoprotein and BCRP, aiming to understand their role in drug resistance and normal physiology.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
  • MDR is often linked to the overexpression of specific transporter proteins that reduce intracellular drug concentrations.

Purpose of the Study:

  • To generate monoclonal antibodies against key MDR-associated proteins.
  • To investigate the role of these proteins in clinical drug resistance.
  • To explore the presence and function of these proteins in normal human tissues.

Main Methods:

  • Development of monoclonal antibodies targeting MDR-associated proteins (e.g., P-glycoprotein, MRPs, BCRP, lung-resistance protein/major vault protein).
  • Application of antibodies in studies of clinical drug resistance.
  • Immunohistochemical analysis of normal human tissues.

Main Results:

  • Successfully generated monoclonal antibodies recognizing multiple MDR-associated proteins.
  • Antibodies are being used to elucidate the specific roles of these proteins in cancer drug resistance.
  • Initial studies explore the expression patterns of these proteins in normal human physiology.

Conclusions:

  • Monoclonal antibodies provide a valuable tool for studying MDR.
  • Further research will clarify the contribution of distinct MDR transporters to clinical resistance and normal biological functions.
  • Understanding these molecular mechanisms may lead to improved cancer therapies.

Related Concept Videos